142 related articles for article (PubMed ID: 36111349)
1. Eczematous eruption after brodalumab successfully treated with guselkumab and dupilumab.
Megna M; Genco L; Noto M; Patruno C; Fabbrocini G; Napolitano M
Dermatol Ther; 2022 Nov; 35(11):e15839. PubMed ID: 36111349
[No Abstract] [Full Text] [Related]
2. Brodalumab-Induced Eczematous Reactions in Psoriasis Patients: Management With Switching to Risankizumab.
Alsenaid A; Piguet V; Lansang P; Miller-Monthrope Y; Yeung J; Joseph M
J Cutan Med Surg; 2023; 27(3):236-240. PubMed ID: 37014149
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab for severe generalized eczematous eruption complicating common variable immunodeficiency.
Votquenne N; Dupire G; Michel O; Ben Said B
Eur J Dermatol; 2021 Feb; 31(1):93-94. PubMed ID: 33586652
[No Abstract] [Full Text] [Related]
4. Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
Danset M; Hacard F; Jaulent C; Nosbaum A; Berard F; Nicolas JF; Goujon C
Eur J Dermatol; 2020 Dec; 30(6):741-743. PubMed ID: 33337328
[No Abstract] [Full Text] [Related]
5. The role of dupilumab in the management of idiopathic chronic eczematous eruption of aging.
Shahriari N; Strober B; Shahriari M
J Am Acad Dermatol; 2020 Nov; 83(5):1533-1535. PubMed ID: 32679275
[No Abstract] [Full Text] [Related]
6. Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany.
Augustin M; Wirth D; Mahlich J; Pepper AN; Druchok C
J Dermatolog Treat; 2022 Mar; 33(2):976-982. PubMed ID: 32663067
[TBL] [Abstract][Full Text] [Related]
7. Recurrence of secukinumab-induced eczematous eruptions after guselkumab treatment for pustular psoriasis.
Miyagawa F; Fukuda K; Mori A; Ogawa K; Asada H
J Dermatol; 2021 Oct; 48(10):E498-E499. PubMed ID: 34212414
[No Abstract] [Full Text] [Related]
8. Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
Xue W; Saharia P; Gray E; Khoudigian-Sinani S; Gaudet V; Barbeau M; Papp K
J Cutan Med Surg; 2020; 24(6):561-572. PubMed ID: 32588642
[TBL] [Abstract][Full Text] [Related]
9. Occupational Chronic Hand Dermatitis in Hospital Environment Successfully Treated with Dupilumab: A Case Report.
Gan H; Gao YD
Iran J Allergy Asthma Immunol; 2022 Aug; 21(4):484-487. PubMed ID: 36243937
[TBL] [Abstract][Full Text] [Related]
10. Eczematous reaction to ixekizumab successfully treated with dupilumab.
Napolitano M; Gallo L; Patruno C; Fabbrocini G; Megna M
Dermatol Ther; 2020 Mar; 33(2):e13218. PubMed ID: 31912951
[No Abstract] [Full Text] [Related]
11. Diagnostic testing of eczematous dermatitis with incomplete response to dupilumab.
Bai H; Murase EM; Ashbaugh AG; Botto NB; Murase JE
J Am Acad Dermatol; 2022 Sep; 87(3):692-695. PubMed ID: 35367296
[No Abstract] [Full Text] [Related]
12. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic hand eczema with dupilumab-A retrospective follow-up study.
Olesen CM; Yüksel YT; Zachariae C; Lund TT; Agner T; Petersen TS; Thyssen JP
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):e557-e559. PubMed ID: 36463422
[No Abstract] [Full Text] [Related]
14. Erythrodermic Psoriasis Successfully Treated With Brodalumab: A Case Series.
Mota F; Mendes-Bastos P
Actas Dermosifiliogr; 2023 Jun; 114(6):T547-T549. PubMed ID: 37172897
[No Abstract] [Full Text] [Related]
15. Erythrodermic Psoriasis Successfully Treated With Brodalumab: A Case Series.
Mota F; Mendes-Bastos P
Actas Dermosifiliogr; 2023 Jun; 114(6):547-549. PubMed ID: 36933615
[No Abstract] [Full Text] [Related]
16. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
Kimura R; Sugita K; Yamamoto O
Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
[No Abstract] [Full Text] [Related]
17. New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab.
Bortoluzzi P; Ferrucci S; Galimberti D; Garavelli F; Pozzo Giuffrida F; Pizzati A; Marzano AV; Mapelli C
Br J Dermatol; 2022 Jan; 186(1):186-187. PubMed ID: 34431510
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review.
Hendricks AJ; Yosipovitch G; Shi VY
J Dermatolog Treat; 2021 Feb; 32(1):19-28. PubMed ID: 31693426
[No Abstract] [Full Text] [Related]
19. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials.
Elewski B; Rich P; Lain E; Soung J; Lewitt GM; Jacobson A
J Dermatolog Treat; 2022 Feb; 33(1):261-265. PubMed ID: 32250714
[TBL] [Abstract][Full Text] [Related]
20. Machine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitis.
Murphy MJ; Hwang E; Singh K; Lee T; Cohen JM; Damsky W
Br J Dermatol; 2023 Dec; 190(1):132-134. PubMed ID: 37818837
[No Abstract] [Full Text] [Related]
[Next] [New Search]
